Scientists in Japan have used CRISPR gene-editing technology to remove the extra chromosome that causes Down syndrome.

Tony told us how the community loved Mikey, who, like many Down syndrome kids, was joyful and enthusiastic. He was the only ...

Down syndrome, resulting from trisomy 21, is associated with a pronounced predisposition to myeloid leukaemias, particularly in childhood. The condition disrupts normal haematopoietic development ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their ...

Jayne Kelly, 30, who pleaded guilty to engaging in reckless conduct after she put a nasal gastric feeding tube into the noses ...

LAVA Therapeutics (LVTX) stock gains as XOMA Royalty (XOMA) agrees to acquire the company for up to $1.24/share plus contingent value rights. Read more here.

Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.

GAAP loss per share of $0.68 beat the analyst estimate by 50% in Q2 2025, and the GAAP net loss narrowed compared to the prior year. GAAP revenue of $2.7 million was slightly above expectations, ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds ...